PP2A-B56-γ Activators
The chemical class known as PP2A-B56-γ Activators comprises a diverse group of compounds that can either directly activate PP2A-B56-γ or indirectly enhance its activity through various signaling pathways and mechanisms. PP2A-B56-γ is a regulatory subunit of PP2A that plays a critical role in dephosphorylating specific substrates to regulate various cellular processes. Compounds like Okadaic Acid and Calyculin A directly inhibit PP2A-B56-γ, leading to the accumulation of phosphorylated substrates and potential activation of downstream pathways. Endothall and Microcystin-LR also inhibit PP2A, including PP2A-B56-γ, leading to increased phosphorylation of target proteins.
On the other hand, compounds like FTY720 (Fingolimod), Forskolin, and cAMP indirectly activate PP2A-B56-γ by modulating the activity of protein kinases like PKA, which can phosphorylate and activate PP2A-B56-γ. NMDA receptor activation and increased intracellular Ca2+ levels can activate Ca2+/calmodulin-dependent PP2A, including PP2A-B56-γ.Dipyridamole increases cAMP levels, indirectly activating PKA and subsequently promoting PP2A-B56-γ dephosphorylation. Prostaglandin E2 (PGE2) also activates PKA, enhancing PP2A-B56-γ activity. Finally, Alsterpaullone inhibits GSK-3β, indirectly activating PP2A-B56-γ by preventing its phosphorylation and inactivation by GSK-3β.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid inhibits PP2A-B56-γ, indirectly increasing the activity of PP2A-B56-γ substrates by blocking its dephosphorylation function. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A inhibits PP2A-B56-γ, leading to the accumulation of phosphorylated substrates and indirectly activating downstream pathways. | ||||||
Endothall | 145-73-3 | sc-201325 sc-201325A | 20 mg 100 mg | $49.00 $203.00 | 1 | |
Endothall inhibits PP2A, including PP2A-B56-γ, leading to increased phosphorylation of target proteins and potential activation of signaling pathways. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
FTY720 activates PP2A-B56-γ indirectly by inhibiting sphingosine kinase, reducing the production of sphingosine-1-phosphate (S1P), which can inhibit PP2A-B56-γ. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates PKA, which can phosphorylate PP2A-B56-γ, increasing its phosphatase activity and potentially enhancing its substrate dephosphorylation. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
cAMP activates PKA, which can phosphorylate PP2A-B56-γ, increasing its phosphatase activity and potentially enhancing its substrate dephosphorylation. | ||||||
N-Methyl-D-Aspartic acid (NMDA) | 6384-92-5 | sc-200458 sc-200458A | 50 mg 250 mg | $109.00 $369.00 | 2 | |
NMDA receptor activation can increase intracellular Ca2+ levels, leading to the activation of Ca2+/calmodulin-dependent PP2A, including PP2A-B56-γ. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole increases cAMP levels by inhibiting phosphodiesterase, indirectly activating PKA and subsequently promoting PP2A-B56-γ dephosphorylation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 activates PKA, which can phosphorylate PP2A-B56-γ, increasing its phosphatase activity and potentially enhancing its substrate dephosphorylation. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits GSK-3β, indirectly activating PP2A-B56-γ by preventing its phosphorylation and inactivation by GSK-3β. | ||||||